Antitumor efficacy of the heparan sulfate mimic roneparstat (SST0001) against sarcoma models involves multi-target inhibition of receptor tyrosine kinases-Reference-Cited by-同舟云学术

Antitumor efficacy of the heparan sulfate mimic roneparstat (SST0001) against sarcoma models involves multi-target inhibition of receptor tyrosine kinases

Published:2016-06-25 Issue:30 Volume:7 Page:47848-47863
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Cassinelli Giuliana¹,Favini Enrica¹,Dal Bo Laura¹,Tortoreto Monica¹,De Maglie Marcella²³,Dagrada Gianpaolo⁴,Pilotti Silvana⁴,Zunino Franco¹,Zaffaroni Nadia¹,Lanzi Cinzia¹

Affiliation:

1. Molecular Pharmacology Unit, Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

2. Department of Veterinary Sciences and Public Health, Università degli Studi di Milano, Milan, Italy

3. Mouse and Animal Pathology Laboratory, Fondazione Filarete, Milan, Italy

4. Laboratory of Experimental Molecular Pathology, Department of Diagnostic Pathology and Laboratory, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. MOLECULAR PATHWAYS AND THERAPEUTIC STRATEGIES IN DERMATOFIBROSARCOMA PROTUBERANS (DFSP): UNRAVELLING THE TUMOR'S GENETIC LANDSCAPE;EXCLI J;2024

2. Potential roles of heparanase in cancer therapy: Current trends and future direction;Journal of Cellular Physiology;2023-03-16

3. Identification of Novel Potential Heparanase Inhibitors Using Virtual Screening;Catalysts;2022-04-30

4. Identification of new therapeutic targets of bone cancers by proteomic strategies;Bone Cancer;2022

5. Upregulation of ERK-EGR1-heparanase axis by HDAC inhibitors provides targets for rational therapeutic intervention in synovial sarcoma;Journal of Experimental & Clinical Cancer Research;2021-12